Pharmacologic Management of High-Risk Neuroblastoma in Children

被引：0
作者：
Veena R. Ganeshan
Nina F. Schor
机构：
[1] University of Rochester School of Medicine and Dentistry,Center for Neural Development and Disease, and Department of Pediatrics
[2] University of Rochester Medical Center,Department of Pediatrics
来源：
Pediatric Drugs | 2011年 / 13卷
关键词：
Neuroblastoma; Topotecan; Minimal Residual Disease; Anaplastic Lymphoma Kinase; Isotretinoin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Neuroblastoma is the most common extracranial solid tumor of childhood. It accounts for 15% of pediatric cancer deaths. Children with high-risk disease have a 3-year event-free survival rate of only 20%. Chemotherapy is the mainstay of treatment in children with advanced neuroblastoma.
引用
收藏
页码：245 / 255
页数：10
相关论文
共 205 条
  • [1] van Noesel MM(2004)Pediatric neuroblastomas: genetic and epigenetic ‘danse macabre’ Gene 325 1-15
  • [2] Versteeg R(2009)Recent advances in neuroblastoma Curr Opin Pediatr 21 350-6
  • [3] Bowen KA(2009)New therapeutic targets for the treatment of highrisk neuroblastoma J Cell Biochem 107 46-57
  • [4] Chung DH(2010)Molecular pathogenesis of peripheral neuroblastic tumors Oncogene 29 1566-79
  • [5] Wagner LM(2008)Neuroblastoma: biology, prognosis, and treatment Pediatr Clin North Am 55 97-120
  • [6] Danks MK(2007)Neuroblastoma Lancet 369 2106-20
  • [7] Janoueix-Lerosey I(2010)Neuroblastoma: what the nurse practitioner should know J Am Acad Nurse Pract 22 236-45
  • [8] Schleiermacher G(1999)Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma N Engl J Med 340 1954-61
  • [9] Delattre O(2010)Predicting outcomes for children with neuroblastoma Discov Med 10 29-36
  • [10] Park JR(2008)Primary care management of the childhood cancer survivor J Pediatr 152 458-66
12345678910